Form D · Biotechnology
Mersana Therapeutics, Inc.
Cambridge, MA · CIK 0001442836
Offering snapshot reported Jun 24, 2016 · SEC filing
- Reported sold
- $33.1M Offering amount: $33.1M
- Investors reported
- 13 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 15, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 24, 2016 | Initial | $33,099,988 | No comparison | 13 | SEC filing |
| Mar 1, 2016 | Amendment | $10,128,576 | $0vs Mar 3, 2015 | 10 | SEC filing |
| Mar 3, 2015 | Initial | $10,128,576 | No comparison | 10 | SEC filing |
| Apr 8, 2014 | Amendment | $14,505,371 | $9,505,377vs Oct 9, 2013 | 10 | SEC filing |
| Oct 9, 2013 | Initial | $4,999,994 | No comparison | 7 | SEC filing |
| Aug 9, 2012 | Initial | $12,500,164 | No comparison | 12 | SEC filing |
| Apr 18, 2012 | Amendment | $10,000,000 | $4,000,000vs Apr 21, 2011 | 7 | SEC filing |
| Apr 21, 2011 | Initial | $6,000,000 | No comparison | 7 | SEC filing |
| Feb 26, 2010 | Initial | $2,500,000 | No comparison | 7 | SEC filing |
| Feb 23, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Aug 12, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-265754
Source: Form D, filed Jun 24, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Nicholas G. Bacopoulos | Director |
| Nicholas G. Bacopoulous | Director |
| Thomas Beck | Director |
| Donald Bergstrom | Executive |
| Burkhard Blank | Executive |
| C. Clarke Boyd | Director |
| C. Boyd Clarke | Director |
| Wayne Foster | Executive |
| Karen Hong | Director |
| Eva Jack | Executive |
| Elaine Jones | Director |
| Michael J. Kaufman | Executive |
| Peter Leone | Executive |
| Timothy Lowinger | Executive |
| Michael Metzger | Executive |
| David Mott | Director |
| Sara Nayeem | Director |
| Julie A. Olson | Director, Executive |
| Peter Park | Executive |
| Anna Protopapas | Director, Executive |
| Joyce Tsang | Director |
| Martin Vogelbaum | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
840 Memorial Drive
Cambridge, MA, 02139
Cambridge, MA, 02139